Stockscreener 앱 받기
37.30
11.16%
-4.695
전일 마감가:
$41.99
열려 있는:
$37.605
하루 거래량:
3.90M
Relative Volume:
0.34
시가총액:
$14.57B
수익:
$3.14B
순이익/손실:
$-3.36B
주가수익비율:
-4.2726
EPS:
-8.73
순현금흐름:
$-4.03B
1주 성능:
-12.77%
1개월 성능:
+8.78%
6개월 성능:
+46.49%
1년 성능:
+20.63%
1일 변동 폭
$36.66
$38.34
1주일 범위
$36.66
$45.50
52주 변동 폭
$22.28
$55.20
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
37.30 | 16.41B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.03 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.15 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
822.60 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.61 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.67 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Equal Weight |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-12 | 개시 | Jefferies | Hold |
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
FDA refuses to review Moderna’s mRNA flu vaccine - BioPharma Dive
The FDA declined to review Moderna’s application for the first mRNA-based flu vaccine, a decision that shocked the company and that comes as the agency plans to tighten federal vaccine approvals. https://wapo.st/4aa88Iz - facebook.com
Moderna Stock Sinks. The Puzzling Reason Its Flu Vaccine Was Rejected. - Barron's
Moderna (MRNA) Stock Falls 9% After FDA Rejects Flu Vaccine Application - Blockonomi
Moderna (MRNA) Faces Setback with FDA Refusal-to-File Letter for Influenza Vaccine - GuruFocus
First Look: Jobs Data Looms; WBD-NFLX Fight, Moderna Setback - GuruFocus
These Stocks Are Today's Movers: Moderna, Robinhood, Shopify, Kraft Heinz, Cloudflare, Humana, Lyft, Mattel, Beta Tech, and More -- Barrons.com - 富途牛牛
FDA Refuses To Review Moderna’s mRNA Flu Vaccine, Claims Trial Inadequacies - BioSpace
FDA declines to review Moderna vaccine application: "It should not be controversial" - medwatch.com
Moderna Stock Sinks. The FDA Delivers a Blow to Its New Flu Vaccine. - Barron's
First mRNA vaccine to be produced in UK approved by regulators - AOL.co.uk
FDA rejects Moderna’s application for mRNA flu shot review - Semafor
Moderna Faces FDA Setback on mRNA Flu Vaccine - TipRanks
The vaccine maker Moderna said that the FDA notified the company that the agency would not review its mRNA flu vaccine, the latest sign of federal health policy that has become hostile to vaccine development. - facebook.com
These Stocks Are Today’s Movers: Moderna, Robinhood, Cloudflare, Lyft, Mattel, Beta Technologies, Gilead, and More - Barron's
Why Is Moderna (MRNA) Stock Down Premarket? FDA Rejects Flu Vaccine Filing - Tokenist
Moderna shares drop after FDA refuses to file for mRNA-1010 influenza vaccine (MRNA:NASDAQ) - Seeking Alpha
FDA refuses to review Moderna’s mRNA flu vaccine application - AOL.com
Why Is Moderna Stock Falling Wednesday?Moderna (NASDAQ:MRNA) - Benzinga
Moderna shares fall after FDA refuses to review new flu vaccine - WKZO
Moderna (MRNA) Stock Plunges as FDA Shuts Door on Flu Vaccine Application - CoinCentral
Moderna (MRNA) Faces Setback as FDA Declines Vaccine Review - GuruFocus
Stocks to Watch Wednesday: Warner/Netflix, Moderna, SLB - The Wall Street Journal
Stocks to Watch Wednesday: Netflix, QXO, Moderna, SLB - The Wall Street Journal
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 - USA Today
Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Rating of "Reduce" from Analysts - MarketBeat
FDA Tosses Flu Vaccine Application Back To Moderna With RTF Letter - Citeline News & Insights
F.D.A. Refuses to Review Moderna Flu Vaccine - The New York Times
Why Did Moderna Stock Tumble Nearly 10% After Hours Today? - Asianet Newsable
Moderna says US refusing to review mRNA-based flu shot - Caledonian Record
Moderna Says US Refusing To Review MRNA-based Flu Shot - Barron's
FDA refuses to review Moderna’s flu vaccine in latest setback - GMToday.com
Moderna Cites Changing Advice As US FDA Refuses To File Flu Vaccine BLA - Citeline News & Insights
FDA Refuses To Review Moderna's Flu Vaccine Application - Health and Me
FDA refuses to review Moderna’s application for mRNA flu vaccine, company says - KRDO
FDA Refuses to Consider Approving Use of Moderna’s New Flu Vaccine - The Wall Street Journal
Moderna (MRNA) Faces FDA Setback with Influenza Vaccine Applicat - GuruFocus
Moderna (MRNA) Shares Decline After FDA Rejects Flu Vaccine Appl - GuruFocus
FDA refuses to review Moderna's flu vaccine application - The Business Journals
Moderna shares slide 7% after FDA refuses to review flu vaccine - Investing.com
FDA Refuses to Review Moderna’s Flu Vaccine in Latest Setback - Bloomberg.com
Moderna says FDA refuses its application for new mRNA flu vaccine - Castanet
FDA refuses to review Moderna’s influenza vaccine application By Investing.com - Investing.com India
Moderna says US FDA refuses to review its influenza vaccine - TradingView
FDA refuses to review Moderna's influenza vaccine application - Reuters
Fda refuses to consider approving use of Moderna's new flu vaccineWSJ - marketscreener.com
Moderna says FDA refuses to review its application for experimental flu shot - CNBC
FDA declines to review Moderna's mRNA flu shot - NBC News
Sector Update: Health Care Stocks Mixed Late Afternoon - marketscreener.com
Moderna signs 5-year vaccine deal with Mexican government - NBC Boston
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico - USA Today
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
모더나 주식 (MRNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| AFEYAN NOUBAR | Director |
Dec 11 '25 |
Sale |
29.48 |
23,853 |
703,306 |
3,924 |
| Bancel Stephane | Chief Executive Officer |
Dec 11 '25 |
Option Exercise |
10.90 |
688,073 |
7,499,996 |
6,181,970 |
1.41%
자본화:
|
볼륨(24시간):